

Influence of parathyroid hormone-related peptide gene in colon cancer cell line growth

Majed S. Alokail, MSc, PhD.

ABSTRACT

Objective: Parathyroid hormone-related peptide (PTHrP) has been found to be expressed in different human tumors including colon. We used a human colon cell line (Lovo) as a model to study the mechanism for the proliferation effects of PTHrP.

Methods: This study was conducted in the Department of Pharmacology at University of Texas Medical Branch, Galveston, Texas, United States of America and Department of Biochemistry at College of Science King Saud University, Riyadh, Kingdom of Saudi Arabia from June 2001 until September 2003. The PTHrP constructs expressing in sense or antisense orientation were constructed by cloning human PTHrP cDNA and transfected into Lovo cells. Single clone of stably

transfected cells was isolated and grown for 2, 4 and 7 days.

Results: The proliferation rate of Lovo clones with sense overexpressing PTHrP was less rapid than that of antisense or empty vector transfected cells; however, at day 7 the cell number of the antisense PTHrP overexpressing clones was more than 2-folds compared with the empty vector transfected clones.

Conclusion: The sense PTHrP gene blocks translation decrease the cell growth, which might be significant implications for the role of PTHrP in colon cancer.

Saudi Med J 2005; Vol. 26 (5): 714-717

Parathyroid hormone-related peptide (PTHrP) was originally known to be the major factor causing the humoral hypercalcemia of malignancy (HHM),¹ and bone metastases development.² It has a significant amino-terminal sequence homology with the biologically active domain of parathyroid hormone (PTH).³ This homology is sufficient for PTHrP-1-34 to confer similar biological action in classical PTH target tissues such as bone and kidney via a common PTH/PTHrP receptor (PTH1R) and elicits PTH-like activity that gives rise to HHM.^{4,5} The PTH/PTHrP receptor is a 7 transmembrane glycoprotein that has been cloned from kidney and osteoblast cell lines,^{6,7} and coupled through G-proteins to a both adenylate cyclase and phospholipase C pathways.^{8,9} Malignancy-associated hypercalcemia is a very common complication in number of cancer patients, since these cancers

frequently secrete high levels of PTHrP¹⁰⁻¹² in both cytoplasm and nucleus of paraffin-embedded tumor specimens.¹³ Although, initially discovered in malignancies, PTHrP known to be produced by most cells and tissues in the body.¹⁴⁻¹⁶ Unlike PTH, PTHrP does not circulate in appreciable amounts in normal subjects but it is thought to exert its effects in an autocrine/paracrine manner.¹⁰ As cancer is predominantly a disease of disordered balance between proliferation, differentiation, and apoptosis, disruptions in the function of the calcium-sensing receptor (CaR) could contribute to the progression of neoplastic disease, and the activation of the CaR has also been linked to increased expression and secretion of PTHrP.¹⁷ In addition to its roles in calcium homeostasis, unrelated functions have been ascribed, including cellular differentiation and modulation of cell growth in normal and

From the Department of Biochemistry, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia.

Received 4th December 2004. Accepted for publication in final form 22nd February 2005.

Address correspondence and reprint request to: Dr. Majed S. Alokail, Department of Biochemistry, College of Science #5, King Saud University, PO Box 2455, Riyadh 11451, Kingdom of Saudi Arabia. Tel. +966 (1) 4675943. Fax. +966 (1) 4675791. E-mail: msalokail@yahoo.com




Figure 1 - Lovo cell line proliferation after expressing of PTHrP gene in sense or antisense orientation. Single clone was isolated, plated at 10^4 cells/well then the cells were trypsinized and counted at day 2, 4 and 7. Each point is the mean \pm SEM of 3 independent experiments. PTHrP - parathyroid hormone-related peptide, +P - means PTHrP construct in sense orientation, -P - means PTHrP construct in antisense orientation, V - means empty vector.




Figure 2 - Rate values of Lovo cell line proliferation expressing PTHrP in the sense or antisense orientation. Each point is the mean \pm SEM of 3 independent experiments. PTHrP - parathyroid hormone-related peptide, +P - means PTHrP construct in sense orientation, -P - means PTHrP construct in antisense orientation, V - means empty vector.

transformed cells such as prostate cancer and renal carcinoma cells.^{18,21} The purpose of this study, therefore, is to investigate the association of the sense and antisense PTHrP gene with colon cancer cell line growth.

Methods. Cell culture. Human epithelial colon tumor cell line (Lovo) were obtained from the European Type Culture Collection (ECCAC). The cells were grown to 80% confluence in defined media (F-12) (Gibco, UK) at 37°C in a humidified 95% O₂, 5% CO₂ atmosphere with 10% fetal bovine serum (FBS), L-glutamine, and 1% penicillin, streptomycin and amphotericin (PSA) (Gibco, UK). The cells were subcultured into 24 well-plates following cell dispersion with 10% trypsin/ethylenediaminetetraacetic acid (EDTA) (Gibco, UK) solution in F-12 medium.

Plasmids. The PTHrP constructs expressing PTHrP in the sense or antisense orientation were constructed by cloning hPTHrP complementary DNA (cDNA) (a generous gift from Dr. Miriam Falzon, Department of Pharmacology, University of Texas Medical Branch, Galveston, USA) coding for amino acids -5 to +139 in the expression vectors pCDNA3.1 (+) or (-) (Invitrogen, UK), respectively [(+) and (-) refer to the orientation of the multiple cloning site within the vector, relative to the direction of transcription from the T7 promoter]. The T7 primer is the upstream primer (5' TAATACGACTCACTATAGGG 3'), and downstream, the pCDNA3.1 reverse primer (5' TAGAAGGCACAGTCGAGG 3'). These primers recognize sequences within the pCDNA3.1 vector.

Transfection design and cell proliferation. The expression vectors pCDNA3.1 (+) or (-) or (v) were

stably transfected into Lovo cell lines with FuGENE 6 (Roche, Germany) transfection according to the manufacturer's specifications. Two days after transfection, 100 μ g/ml G418 (Gibco, UK) was added, and resistant clones were selected. Single clones of stably transfected cells was isolated by limiting dilution and plated in 24 well plates at 10⁴ cells/well then transferred to 6 well plates and cultured in medium containing 100 μ g/ml G418. The cells were then trypsinized and counted at day 2, 4 and 7 in Coulter counter (Coulter Electronics Inc., USA).

Statistical analysis. All data are representative of 3 independent experiments. The statistical significance was defined using t tests, with thresholds of $p < 0.05$, $p < 0.001$.

Results. The proliferation rate of Lovo clones (+P) overexpressing PTHrP was less rapid than that of empty vector; however, after 7 days incubation the cell number of the PTHrP overexpressing clones (-P) was more than 2-folds compared with the empty vector transfected clones (V). The growth rate of antisense PTHrP transfected clones was significantly less than that of the empty vector-transfected clones (Figure 1). The percentage differences in the rate of proliferation of the sense and antisense transfected cells compared with empty vector transfected cells was shown in Figure 2. At day 4, the percentage rate of proliferation of empty vector transfected cells was almost the same as that of the sense vector transfected cells. However, at day 7 in culture the percentage of sense vector transfected cells were significantly high ($p < 0.001$) than the antisense and empty vector transfected cells.

DISCUSSION. In cancer patients, the effects of PTHrP on calcium levels are mediated via PTHrP entering the circulation and activating the PTH1R in classic PTH organs (such as bone and kidney), resulting in HHM.^{22,23} Parathyroid hormone-related peptide modulates growth in prostate and breast cancer cells,^{20,24,25} Leydig tumor cells,²⁶ renal carcinoma cells,²¹ osteoblasts²⁷ and pancreas.²⁸ Proliferative and antiproliferative effects seem to be dependent on the cell type. Parathyroid hormone-related peptide has joined the ever-increasing list of peptide hormones and growth factors that elicit their biological responses in a dual manner, through interaction with cell surface receptors linked to signal transduction cascades and through intranuclear localization.²⁹ Parathyroid hormone-related peptide contains a signal sequence that directs the nascent peptide to the secretory pathway, must avoid the endoplasmic reticulum and remain in the cytoplasmic compartment before its nuclear translocation. Various potential mechanisms have been proposed, which include the use of alternative, non-adenine, uracil, guanine (AUG) translational start sites, internalization of the ligand-receptor complex by endocytosis, and reverse translocation or dislocation from the endoplasmic reticulum lumen to the cytoplasm.^{29,30}

Our results show that the inhibition of PTHrP synthesis using an antisense oligodeoxynucleotide blocks translation of the peptide and decrease the Lovo cell proliferation. The effect of autocrine/paracrine and intracrine effects of PTHrP in Lovo cells overproducing the peptide is accelerated cell growth. Many studies have shown that PTHrP also acts in an intracrine fashion after translocation to the nucleus or nucleolus.^{19,31-33} The PTHrP action through the autocrine/paracrine pathway exerts an antiproliferative effect. These results differ from those of Birch et al,³⁴ who found a mitogenic response to PTHrP in breast cell line. In our current study, we show that overexpression of PTHrP in Lovo cells results in a dramatic stimulatory effect on cell proliferation (**Figure 1**). Massfelder et al¹⁹ reported a similar effect in vascular smooth muscle cells, and Henderson et al³² have shown that nuclear PTHrP is associated with an inhibitory effect on apoptosis. Although PTHrP is clearly targeted to the nucleus in a number of systems such as vascular smooth muscle cells,¹⁹ and a nucleolar localization in chondrocytes and osteoblasts,³² and in a human keratinocyte cell line.³³ In addition, cell type specific expression of PTHrP mRNA isoforms occurred between the various cell line.³⁵ At present, it is unknown whether this difference is a reflection of the different cell types under study. It is unknown at this time the mechanism by which nuclear accumulation of PTHrP activates the cell cycle, thereby increasing

proliferation in number of cell types.^{19,24,32,33} The peptide may interact with key proteins involved in cell cycle regulation or with nucleic acids via an intracrine pathway independent of its classical nuclear localization sequence.³⁶ This novel pathway could mediate the effects of PTHrP on tumor progression. Recent study has shown that the peptide can interact with both homopolymeric and total cellular ribonucleic acid (RNA).³⁷ As the nucleolus is the major site for biogenesis of ribosomes, nucleolar PTHrP may influence cellular functions by modulating ribosomal RNA synthesis, either by affecting RNA polymerase I activity or by altering ribosome assembly or function, or both. In summary, this study shows that PTHrP produces opposing mitogenic and antimitogenic actions in the colon cancer Lovo cell line. Using PTHrP sense oligodeoxynucleotide, our data confirm that the PTHrP decreases cell proliferation when acting via the autocrine/paracrine pathway, mediated through the cell surface PTH1R.

In conclusion, when acting through the intracrine pathway, the peptide dramatically stimulates cell growth. The proliferative effects of overexpressed PTHrP seem to predominate, in that overexpression of the peptide results in accelerated cell growth. Inhibition of PTHrP synthesis using a sense oligodeoxynucleotide resulted in a net decrease in Lovo cell proliferation. The net effect of autocrine/paracrine and intracrine effects of PTHrP in Lovo cells overproducing the peptide is accelerated cell growth. As PTHrP imparts a growth advantage to colon cancer cells, we suggested the findings may lead to the development of future PTHrP therapeutic strategies for colon cancer treatment.

Acknowledgment. This work was funded by the King Abdul-Aziz City for Science and Technology (KACST), Riyadh, Kingdom of Saudi Arabia for their support of this work (MS-7-50). We thank Dr. Miriam Falzon, Department of Pharmacology, University of Texas Medical Branch, Galveston, USA for her generous gift of hPTHrP cDNA.

References

- Moseley JM, Kubota M, Diefenbach-Jagger H, Wetenhall REH, Kemp BE, Suva LJ, et al. Parathyroid hormone-related protein purified from a human lung cancer cell line. *Proc Natl Acad Sci U S A* 1987; 84: 5048-5052.
- Linforth R, Anderson N, Hoey R, Nolan T, Downey S, Brady G, et al. Coexpression of parathyroid hormone related protein and its receptor in early breast cancer predicts poor patient survival. *Clin Cancer Res* 2002; 8: 3172-3177.
- Mangin M, Webb AC, Dreyer BE, Posilloco JT, Ikeda K, Weir EC, et al. Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy. *Proc Natl Acad Sci U S A* 1988; 85: 597-601.
- Moseley JM, Gillespie MT. Parathyroid hormone-related protein. *Crit Rev Clin Lab Sci* 1995; 32: 299-343.

5. Valin A, Guillen C, Esbrit P. C-terminal parathyroid hormone-related protein (PTHrP) (107-139) stimulates intracellular Ca²⁺ through a receptor different from the type 1 PTH/PTHrP receptor in osteoblast osteosarcoma UMR 106 cells. *Endocrinology* 2001; 142: 2752-2759.
6. Jümpfer H, Abou-Samra A-B, Ueno S, Gu, WX, Potts, JR, Segre GV. The parathyroid hormone-like peptide associated with humoral hypercalcemia of malignancy and parathyroid hormone bind to the same receptor on the plasma membrane of ROS 17/2.8 cells. *J Biol Chem* 1988; 263: 8557-8560.
7. Nissenson RA, Diep D, Strewler GJ. Synthetic peptides comprising the amino-terminal sequence of a parathyroid hormone-like protein from human malignancies. Binding to parathyroid hormone receptors and activation of adenylate cyclase in bone cells and kidney. *J Biol Chem* 1988; 263: 12866-12871.
8. Karpf DB, Arnaud CD, King K. The canine renal parathyroid hormone receptor is a glycoprotein: characterization and partial purification. *Biochemistry* 1987; 26: 7825-7833.
9. Teitelbaum AP, Nissenson RA, Arnaud, CD. Coupling of the canine renal parathyroid hormone receptor to adenylate cyclase: modulation by guanyl nucleotides and N-ethylmaleimide. *Endocrinology* 1982; 111: 1524-1533.
10. Southby J, Kissin MW, Danks JA, Hayman JA, Moseley JM, Henderson MA, et al. Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. *Cancer Res* 1990; 50: 7710-7716.
11. Ikeda K, Mangin M, Dreyer BE, Webb AC, Posillico JT, Stewart AF, et al. Identification of transcripts encoding a parathyroid hormone-like peptide in messenger RNAs from a variety of human and animal tumors associated with humoral hypercalcemia of malignancy. *J Clin Invest* 1988; 81: 2010-2016.
12. Francini G, Maiolo E, Petriolo E, Paffetti P, Gonnelli S, Aquino A. Production of parathyroid hormone and parathyroid hormone-related protein by breast cancer cells in culture. *J Cancer Res Clin Oncol* 1993; 119: 421-425.
13. Bouvet M, Nardin SR, Burton DW, Lee NC, Yang M, Wang X et al. Parathyroid hormone-related protein as a novel tumor marker in pancreatic adenocarcinoma. *Pancreas* 2002; 24: 284-290.
14. Philbrick WM, Wysolmerski JJ, Galbraith S, Holt E, Orloff JJ, Yang KH, et al. Defining the role of parathyroid hormone-related protein in normal physiology. *Physiol Rev* 1996; 76: 127-173.
15. Alokail MS. Potential regulation of PTH/PTHrP receptor expression in choriocarcinoma JAR cell line. *Saudi Med J* 2004; 25: 615-620.
16. Karaplis AC, Luz A, Glowacki J, Bronson RT, Tybulewicz VL, Kronenberg H et al. Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. *Genes Dev* 1994; 8: 277-289.
17. Rodland KD. The role of the calcium-sensing receptor in cancer. *Cell Calcium* 2004; 35: 291-295.
18. Kaiser SM, Laneville P, Bernier SM, Rhim JS, Kremer R, Goltzman D. Enhanced growth of a human keratinocyte cell line induced by antisense RNA for parathyroid hormone-related peptide. *J Biol Chem* 1992; 267: 13623-13628.
19. Massfelder T, Dann P, Wu TL, Vasavada R, Helwig J-J, Stewart AF. Opposing mitogenic and antimitogenic actions of parathyroid hormone-related protein in vascular smooth muscle cells: a critical role for nuclear targeting. *Proc Natl Acad Sci U S A* 1997; 94: 13630-13635.
20. Iwamura M, Abrahamson PA, Foss KA, Wu G, Cockett AT, Deftos LJ. Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. *Urology* 1994; 43: 675-679.
21. Burton PBJ, Moniz C, Knight DE. Parathyroid hormone related peptide can function as an autocrine growth factor in human renal cell carcinoma. *Biochem Biophys Res Commun* 1990; 167: 1134-1138.
22. Burtis WJ, Wu T, Bunch C, Wysolmerski JJ, Insogna, KL, Weir EC, et al. Identification of a novel 17,000 dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. *J Biol Chem* 1987; 262: 7151-7156.
23. Broadus AE, Mangin M, Ikeda K, Insogna KL, Weir EC, Burtis WJ, et al. Humoral hypercalcemia of cancer. *N Engl J Med* 1988; 319: 556-563.
24. Falzon M, DU P. Enhanced growth of MCF7 breast cancer cells overexpressing parathyroid hormone-related peptide. *Endocrinology* 2000; 141: 1881-1892.
25. Shen X, Qian L, Falzon M. PTH-related protein enhances MCF7 breast cancer cell adhesion, migration, and invasion via an intracrine pathway. *Exp Cell Res* 2004; 294: 420-433.
26. Rabbani SA, Gladu J, Liu B, Goltzman D. Regulation in vivo of the growth of Leydig tumors by antisense ribonucleic acid for parathyroid hormone-related peptide. *Endocrinology* 1995; 136: 416-422.
27. Li X, Drucker DJ. Growth factor-like properties of parathyroid hormone-related peptide in transformed rodent cells. *Cancer Res* 1993; 53: 2980-2986.
28. Gizesiak JJ, Clopton P, Chalberg C, Smith K, Burton DW, Silletti S, et al. The extracellular matrix differentially regulates the expression of PTHrP and the PTH/PTHrP receptor in FG pancreatic cancer cells. *Pancreas* 2004; 29: 85-92.
29. Henderson JE. Nuclear targeting of secretory proteins. *Mol Cell Endocrinol* 1997; 129: 1-5.
30. Nguyen MTA, Karaplis AC. The nucleus: a target site for parathyroid hormone-related peptide (PTHrP) action. *J Cell Biochem* 1998; 70: 193-199.
31. Kaiser SM, Sebag M, Rhim JS, Kremer R, Goltzman D. Antisense-mediated inhibition of parathyroid hormone-related peptide production in a keratinocyte cell line impedes differentiation. *Mol Endocrinol* 1994; 8: 139-147.
32. Henderson JE, Amikazu N, Warshawsky H, Biasotto D, Lanske BM, Goltzman D, et al. Nuclear localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death. *Mol Cell Biol* 1995; 15: 4064-4075.
33. Lam MHC, Olsen SL, Rankin WA, Ho PW, Martin TJ, Gillespie MT, et al. PTHrP and cell division: expression and localization of PTHrP in a keratinocyte cell line (HaCaT) during the cell cycle. *J Cell Physiol* 1997; 173: 433-446.
34. Birch MA, Carron JA, Fraser WD, Gallagher JA. Parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor expression and mitogenic responses in human breast cancer cell lines. *Br J Cancer* 1995; 72: 90-95.
35. Sellers RS, Luchin AI, Richard V, Brena RM, Lima D, Rosol TJ. Alternative splicing of parathyroid-related protein mRNA: expression and stability. *J Mol Endocrinol* 2004; 33: 227-241.
36. Lehrer S, Diamond EJ, Mankine B, Stone NN, Stock RG. Serum interleukin-8 is elevated in men with prostate cancer and bone metastasis. *Technol Cancer Res Treat* 2004; 3: 411-412.
37. Aarts MA, Levy D, He B, Stregger S, Chen T, Richard S, et al. Parathyroid hormone-related protein interacts with RNA. *J Biol Chem* 1999; 274: 4832-4838.